Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Xenetic Biosciences Inc's Business Segments
Xenetic Biosciences Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Royalty Revenue
Total Revenue
$ 1
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Royalty Revenue0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Royalty Revenue | $ 1 | - |
Revenue by Product & Service Category - FY
- Royalty Revenue0%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Royalty Revenue | $ 1 | - |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- Royalty Revenue0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Royalty Revenue | $ 1 | - |
Description of Xenetic Biosciences Inc
Xenetic Biosciences Inc. is a biopharmaceutical company that specializes in developing novel therapies for the treatment of rare diseases. The company was founded in 2014 and is headquartered in Framingham, Massachusetts, with additional operations and research facilities in the UK.
One of Xenetic Biosciences' main focuses is the development of proprietary drug candidates using its unique PolyXen technology platform. This platform enables the company to modify existing drugs with biodegradable polysaccharides, enhancing their therapeutic properties and improving patient outcomes.
PolyXen technology allows Xenetic Biosciences to improve drug safety, efficacy, and dosing frequency by extending the drug's half-life and reducing immunogenicity. The technology can be applied to various therapeutic areas, including oncology, rare diseases, and vaccines.
In the field of rare diseases, Xenetic Biosciences is actively developing treatments for conditions with significant unmet medical needs. One of its lead drug candidates, XBIO-101, is being developed for the treatment of progesterone receptor-negative endometrial cancer, a rare and aggressive form of cancer. XBIO-101 has shown promising results in early clinical trials and is currently being evaluated in later-stage studies.
Xenetic Biosciences also has a strategic partnership with Takeda Pharmaceutical Company Limited, a global biopharmaceutical company. Under this partnership, the companies are jointly developing a treatment for hemophilia, leveraging Xenetic's PolyXen technology with Takeda's expertise in this therapeutic area.
Beyond its proprietary programs, Xenetic Biosciences also offers its PolyXen technology on a contract basis to other pharmaceutical companies, allowing them to enhance the performance of their own drug candidates. This contract manufacturing service provides an additional revenue stream for the company and strengthens its position in the biopharmaceutical industry.
In addition to its drug development activities, Xenetic Biosciences is focused on strategic collaborations and partnerships to accelerate the development of its pipeline. The company has a network of research and academic collaborations, enabling it to access cutting-edge science and expertise in specific disease areas.
Overall, Xenetic Biosciences Inc. is a biopharmaceutical company at the forefront of developing innovative therapies for rare diseases. Its proprietary PolyXen technology platform, strategic collaborations, and contract manufacturing capabilities position it as a leader in the field, with the potential to make a significant impact on the lives of patients suffering from serious and rare conditions.
One of Xenetic Biosciences' main focuses is the development of proprietary drug candidates using its unique PolyXen technology platform. This platform enables the company to modify existing drugs with biodegradable polysaccharides, enhancing their therapeutic properties and improving patient outcomes.
PolyXen technology allows Xenetic Biosciences to improve drug safety, efficacy, and dosing frequency by extending the drug's half-life and reducing immunogenicity. The technology can be applied to various therapeutic areas, including oncology, rare diseases, and vaccines.
In the field of rare diseases, Xenetic Biosciences is actively developing treatments for conditions with significant unmet medical needs. One of its lead drug candidates, XBIO-101, is being developed for the treatment of progesterone receptor-negative endometrial cancer, a rare and aggressive form of cancer. XBIO-101 has shown promising results in early clinical trials and is currently being evaluated in later-stage studies.
Xenetic Biosciences also has a strategic partnership with Takeda Pharmaceutical Company Limited, a global biopharmaceutical company. Under this partnership, the companies are jointly developing a treatment for hemophilia, leveraging Xenetic's PolyXen technology with Takeda's expertise in this therapeutic area.
Beyond its proprietary programs, Xenetic Biosciences also offers its PolyXen technology on a contract basis to other pharmaceutical companies, allowing them to enhance the performance of their own drug candidates. This contract manufacturing service provides an additional revenue stream for the company and strengthens its position in the biopharmaceutical industry.
In addition to its drug development activities, Xenetic Biosciences is focused on strategic collaborations and partnerships to accelerate the development of its pipeline. The company has a network of research and academic collaborations, enabling it to access cutting-edge science and expertise in specific disease areas.
Overall, Xenetic Biosciences Inc. is a biopharmaceutical company at the forefront of developing innovative therapies for rare diseases. Its proprietary PolyXen technology platform, strategic collaborations, and contract manufacturing capabilities position it as a leader in the field, with the potential to make a significant impact on the lives of patients suffering from serious and rare conditions.
Xenetic Biosciences Inc. is a biotechnology company focused on developing novel and proprietary technologies for the development of biologic and therapeutic products. The company works primarily in the areas of drug delivery, biologics, and complex biologics, with a particular emphasis on the use of its proprietary drug delivery platforms to enhance the efficacy of existing therapies or to create new therapies for various medical applications. Below are key segments, products, and services offered by Xenetic Biosciences:
1. Drug Delivery Platforms
Xenetic has developed several advanced drug delivery platforms designed to improve the pharmacokinetics and bioavailability of therapeutic agents.
- Xenetics Molecular Packaging Technology (MPT): This technology is aimed at enhancing the delivery of both small molecules and large biologics. By encapsulating drugs within a biocompatible and biodegradable matrix, MPT aims to improve drug solubility and stability, thereby enhancing therapeutic potential.
- Polymeric Micelles: This platform focuses on the creation of nano-sized drug carriers that increase the solubility and circulation time of hydrophobic drugs. This approach is particularly beneficial for cancer therapies and treatments requiring sustained release of the active ingredient.
Therapeutic Products
Xenetic is involved in the development of various therapeutic products, particularly in oncology and immunotherapy.
- Oncology Products: The company is working on several anti-cancer therapeutics that utilize its drug delivery systems to improve the targeting and efficacy of cancer drugs, thereby reducing side effects while enhancing the therapeutic impact.
- Immunotherapies: Xenetic is also focused on developing immunotherapeutic products that leverage its advanced drug delivery systems to create more effective treatments for various immune-related conditions, including autoimmune diseases and cancer.
Collaborative Development and Licensing
Xenetic actively seeks partnerships with other biotechnology and pharmaceutical companies to collaborate on development projects. This not only helps in the pooling of resources and expertise but also enables the advancement of innovative therapies through shared knowledge and technology licensing.
- Technology Licensing Agreements: The company offers its proprietary technologies to other organizations for development or commercialization, allowing partners to leverage Xenetic’s platforms in their own product development pipelines.
Research and Development Services
Xenetic provides tailored R&D services aimed at supporting partners in the drug development process.
- Formulation Development: The company offers formulation development services to enhance the solubility, stability, and delivery mechanisms of drug candidates.
- Clinical Development Support: Xenetic assists in the clinical development phases, providing expertise in regulatory strategy and compliance, study design, and execution to help bring products to market effectively.
Specialty Products
Xenetic is also involved in the creation of specialized products that cater to niche markets or specific medical needs.
- Rare Diseases: The company may develop treatments for rare diseases where traditional therapies are lacking or ineffective, leveraging its drug delivery platforms to create more accessible therapies.
Conclusion
Xenetic Biosciences Inc. is positioned as an innovative player in the biotechnology industry, emphasizing the importance of proprietary drug delivery systems and collaborative partnerships in developing its therapeutic products. With a focus on providing advanced solutions for complex medical challenges, Xenetic’s diverse offerings encompass a range of technologies and therapeutic approaches aimed at improving patient outcomes across oncology and immunological conditions. The company continues to expand its portfolio and collaborate with industry partners, underscoring its commitment to advancing biopharmaceutical development.
1. Drug Delivery Platforms
Xenetic has developed several advanced drug delivery platforms designed to improve the pharmacokinetics and bioavailability of therapeutic agents.
- Xenetics Molecular Packaging Technology (MPT): This technology is aimed at enhancing the delivery of both small molecules and large biologics. By encapsulating drugs within a biocompatible and biodegradable matrix, MPT aims to improve drug solubility and stability, thereby enhancing therapeutic potential.
- Polymeric Micelles: This platform focuses on the creation of nano-sized drug carriers that increase the solubility and circulation time of hydrophobic drugs. This approach is particularly beneficial for cancer therapies and treatments requiring sustained release of the active ingredient.
Therapeutic Products
Xenetic is involved in the development of various therapeutic products, particularly in oncology and immunotherapy.
- Oncology Products: The company is working on several anti-cancer therapeutics that utilize its drug delivery systems to improve the targeting and efficacy of cancer drugs, thereby reducing side effects while enhancing the therapeutic impact.
- Immunotherapies: Xenetic is also focused on developing immunotherapeutic products that leverage its advanced drug delivery systems to create more effective treatments for various immune-related conditions, including autoimmune diseases and cancer.
Collaborative Development and Licensing
Xenetic actively seeks partnerships with other biotechnology and pharmaceutical companies to collaborate on development projects. This not only helps in the pooling of resources and expertise but also enables the advancement of innovative therapies through shared knowledge and technology licensing.
- Technology Licensing Agreements: The company offers its proprietary technologies to other organizations for development or commercialization, allowing partners to leverage Xenetic’s platforms in their own product development pipelines.
Research and Development Services
Xenetic provides tailored R&D services aimed at supporting partners in the drug development process.
- Formulation Development: The company offers formulation development services to enhance the solubility, stability, and delivery mechanisms of drug candidates.
- Clinical Development Support: Xenetic assists in the clinical development phases, providing expertise in regulatory strategy and compliance, study design, and execution to help bring products to market effectively.
Specialty Products
Xenetic is also involved in the creation of specialized products that cater to niche markets or specific medical needs.
- Rare Diseases: The company may develop treatments for rare diseases where traditional therapies are lacking or ineffective, leveraging its drug delivery platforms to create more accessible therapies.
Conclusion
Xenetic Biosciences Inc. is positioned as an innovative player in the biotechnology industry, emphasizing the importance of proprietary drug delivery systems and collaborative partnerships in developing its therapeutic products. With a focus on providing advanced solutions for complex medical challenges, Xenetic’s diverse offerings encompass a range of technologies and therapeutic approaches aimed at improving patient outcomes across oncology and immunological conditions. The company continues to expand its portfolio and collaborate with industry partners, underscoring its commitment to advancing biopharmaceutical development.